Nicotine Dependence Clinical Trial
Official title:
Assessing Top Down and Bottom Up Attention Mechanisms in Smokers Using Nicotine Nasal Spray
Background:
- Smoking is the leading cause of preventable death in the United States, and researchers
are interested in gaining a better understanding of the perceived beneficial effects of
nicotine to help improve treatment strategies for nicotine dependence. Understanding the
conditions under which nicotine improves attention and cognitive processing may provide
more useful information for this research.
- The ability to pay attention and filter relevant from irrelevant stimuli is central to
all aspects of information-processing. Top-down and bottom-up attentional processes
illustrate how the brain combines stimuli and goal-directed behaviors. Bottom-up
processing is an unconscious response to sensory input; for instance, when the eyes
automatically focus on a prominent image in a picture. Top-down processing is a
conscious response to drive attention toward specific stimuli; for instance, when a
person is asked to focus on a less immediately noticeable image in a picture.
Researchers are interested in determining whether nicotine improves cognitive
performance by acting on top-down or bottom-up attentional mechanisms.
Objectives:
- To investigate the effect of nicotine on the top-down and bottom-up mechanisms of attention
in cigarette smokers.
Eligibility:
- Current smokers (at least 10 cigarettes per day for at least 1 year) between 18 and 55
years of age.
Design:
- This study will involve one training session and four experimental sessions.
- During the training session, participants will receive a sample dose of the nicotine
nasal spray used in the study to determine if they can tolerate the effects.
- For each experimental session, participants will receive one dose of nicotine nasal
spray (1 mg, 2 mg, or 3 mg) or placebo spray, followed by blood pressure and heart rate
monitoring, performance of an attentional test, and questionnaires to rate participants
perception of nicotine effectiveness. Participants may receive different doses at
different sessions, and will not be told which dose they will receive at any given
point.
Objective:
The objective is to investigate the dose-response effect of nicotine on the top-down and
bottom-up mechanisms of attention in cigarette smokers.
Study population:
Male and nonpregnant-female smokers 18 to 55 years of age.
Design:
This study is a double-blind, placebo controlled trial of nicotine or placebo nasal sprays.
Participants have five visits: a training session and four experimental sessions. Each
participant receives a test dose of the nasal spray immediately following the training
session to ascertain tolerability and become familiarized with the effect of the spray. One
dose (0, 1.0, 2.0 or 3.0 mg) of nicotine nasal spray is administered at the beginning of each
experimental session followed by the test battery.
Outcome Measures:
Outcome measures are vital signs, ratings of mood and drug effect, and performance (accuracy,
response time) on a test of selective attention.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05176418 -
IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate
|
Early Phase 1 | |
Completed |
NCT04084210 -
Impact of Alternative Nicotine-Delivery Products on Combustible Cigarette Use
|
Phase 2 | |
Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
Withdrawn |
NCT03707600 -
State and Trait Mediated Response to TMS in Substance Use Disorder
|
N/A | |
Recruiting |
NCT03999099 -
Targeting Orexin to Treat Nicotine Dependence
|
Phase 1 | |
Completed |
NCT03847155 -
Prevention of Nicotine Abstinence in Critically Ill Patients After Major Surgery
|
N/A | |
Completed |
NCT02840435 -
Study on Sit to Quit Phone Intervention
|
N/A | |
Completed |
NCT02139930 -
Project 2: Strategies for Reducing Nicotine Content in Cigarettes
|
N/A | |
Completed |
NCT01982110 -
A Mindfulness Based Application for Smoking Cessation
|
N/A | |
Completed |
NCT01926626 -
Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers
|
Phase 2 | |
Withdrawn |
NCT01569477 -
Striving to Quit-Wisconsin Tobacco Quit Line
|
N/A | |
Completed |
NCT01569490 -
Striving to Quit: First Breath
|
N/A | |
Completed |
NCT01632189 -
The Effect of Varenicline on D2/D3 Receptor Binding in Smokers
|
N/A | |
Completed |
NCT01685996 -
Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01182766 -
New Treatment for Alcohol and Nicotine Dependence
|
Phase 2/Phase 3 | |
Completed |
NCT01061528 -
Coping Skills Treatment for Smoking Cessation
|
N/A | |
Completed |
NCT00996034 -
Nicotine Vaccination and Nicotinic Receptor Occupancy
|
Phase 2 | |
Withdrawn |
NCT01589081 -
Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect
|
N/A | |
Suspended |
NCT01636336 -
Effects of Progesterone on Smoked Nicotine Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effects
|
N/A | |
Completed |
NCT01943994 -
Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study
|
N/A |